tiprankstipranks
NewsSmart PortfolioMarkets
Research Tools
Top Stocks
Top Smart Score Stocks
New
Analysts' Top StocksInsiders' Hot Stocks
Popular
Trending Stocks
Daily Feeds
Daily Stock RatingsDaily Insider Transactions
Comparisons
Stock ComparisonElectronic Vehicles Stocks
New
Coronavirus Vaccine StocksFAANG Stocks
Popular
High Dividend StocksBitcoin Stocks
Screeners
Stock ScreenerPenny Stocks
New
Smart Portfolio
My Portfolio
OverviewMy HoldingsMy Portfolio AnalysisCrowd Insights
My Watchlist
Stock WatchlistExpert Watchlist
Profile & Performance
My PerformanceMy Public Profile
New
Top Experts
Find & Follow Experts
My ExpertsExpert CenterTop Firms
Top Lists
Top 25 Wall Street AnalystsTop 25 Financial BloggersTop 25 Corporate InsidersTop 25 Hedge Fund ManagersTop Individual Investors
New
News
Categories
HomeMarket NewsTipRanks LabsIdeas & InsightsStock Analysis
Trending Topics
Coronavirus StocksDividend StocksPenny StocksFAANG Stocks
Calendars
Calendars & Events
Earnings CalendarsDividend CalendarsStock Market HolidaysIPO Calendar
About Us
About TipRanksEnterprise SolutionsBecome an AffiliateCareersContact Us
NewsSmart PortfolioMarketsNotifications
All News

AMRN

Topic
Amarin: Could the New CEO Help Vazkepa’s European Push?
There’s a big change in Amarin’s (AMRN) C-Suite and it looks like the Street is not happy about...
Marty Shtrubel
AMRN
Amarin Pops 23% on Encouraging Late-Stage Vascepa Data from China Trial
Shares of Amarin surged 23% in after-hours trading on Thursday after it reported favorable and statistically significant top-line...
Maya Sasson
AMRN
Good Entry Point for Amarin Stock? Not Just Yet, Says Analyst
Many companies will be glad to put 2020 behind them and you can certainly add Amarin (AMRN) to...
Marty Shtrubel
AMRN
Amarin Pops 4% After-Hours On Positive PCI Data For Vascepa
Shares in Amarin (AMRN) popped 4% in Thursday’s after hours trading after the company presented encouraging data on...
Harriet Lefton
AMRN
Amarin Stock at $12 a Share? This Analyst Thinks It’s Possible
If you are looking for another successful biotech story in 2020, then look away now. Shares of Amarin...
Marty Shtrubel
AMRN
Amarin (AMRN): Vascepa’s International Opportunity Remains Intact, Says Analyst
The markets might be in turmoil, but spare a thought for the current woes at biotech Amarin (AMRN)....
Marty Shtrubel
AMRN
Amarin (AMRN) Bears the Brunt of a Price Target Cut
The appeal hearing for Amarin’s (AMRN) high triglyceride treatment Vascepa kicked off on Wednesday and ended on a...
Marty Shtrubel
AMRN
Can Amarin Win Its Vascepa Appeal Case? Analyst Weighs In
It is gearing up to be a big week for Amarin (AMRN), as it awaits the opening of...
Marty Shtrubel
AMRN
Amarin’s Vascepa To Take Part In Covid-19 Study In Adults With Heart Disease
Amarin announced on Friday that Kaiser Permanente Northern California (KPNC) is initiating a trial to study the potential of...
Sharon Wrobel
AMRN
Amarin: Improving HCP Access Should Drive More Vascepa Sales, Says Analyst
Keeping it simple, biotech Amarin (AMRN) has one product. This means the company can focus solely on the...
Marty Shtrubel
AMRN
Amarin (AMRN) Stock Will Likely Stay Range-Bound Near-Term, Says Analyst
2020 may have witnessed skyrocketing rallies for some biotechs, but it most certainly hasn’t been kind to Amarin...
Marty Shtrubel
AMRN
Can Amarin Soar 420% Over the Next Year? This Analyst Thinks So
Amarin (AMRN) is seriously undervalued, according to Cantor analyst Louise Chen. On Monday, the drug maker presented encouraging...
Marty Shtrubel
AMRN
Amarin, Apotex Settle Vascepa Dispute; Analyst Stays Sidelined
Amarin (AMRN) has announced a settlement agreement with Apotex Inc. that resolves a patent litigation over Apotex’s abbreviated...
Harriet Lefton
AMRN
Too Much Uncertainty Keeps This 5-Star Analyst Watching Amarin Stock From the Sidelines
Rewind to the end of 2019, and in the dead of winter, the sun appeared to be shining...
Marty Shtrubel
AMRN
Will Courts Reverse Earlier Ruling on Amarin Patents? Analyst Weights In
It has been a rough couple of months for pharma company Amarin Corporation (AMRN). At the end of...
Maya Sasson
AMRN
Amarin Down 10% in Pre-Market On Generic Approval
Shares in Amarin (AMRN) are plunging 10% in Friday’s pre-market trading on the news that Hikma Pharmaceuticals (HKMPY)...
Harriet Lefton
AMRN
Can Amarin (AMRN) Overcome Its Patent Headwinds? 5-Star Analyst Weighs In
The Amarin (AMRN) vs the Generics drama has entered a new stage. For the uninitiated, a quick recap:...
Marty Shtrubel
AMRN